Tandem Historical Financial Ratios
TNDM Stock | USD 35.15 2.38 6.34% |
Tandem Diabetes is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 5.28, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.15 will help investors to properly organize and evaluate Tandem Diabetes Care financial condition quickly.
Tandem |
About Tandem Financial Ratios Analysis
Tandem Diabetes CareFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Tandem Diabetes investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Tandem financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Tandem Diabetes history.
Tandem Diabetes Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Tandem Diabetes Care stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tandem Diabetes sales, a figure that is much harder to manipulate than other Tandem Diabetes Care multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Tandem Diabetes' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Days Sales Outstanding is very stable compared to the past year. As of the 18th of January 2025, Stock Based Compensation To Revenue is likely to grow to 0.15, while PTB Ratio is likely to drop 4.71.
2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 6.97 | 7.66 | 6.9 | 8.12 | Days Of Inventory On Hand | 104.47 | 151.69 | 174.45 | 176.39 |
Tandem Diabetes fundamentals Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 11.7 | 13.49 | 3.6 | 2.57 | 2.95 | 2.81 | |
Ptb Ratio | 15.93 | 21.89 | 6.55 | 6.12 | 5.51 | 4.71 | |
Days Sales Outstanding | 60.14 | 57.51 | 52.26 | 51.53 | 59.26 | 92.58 | |
Book Value Per Share | 6.01 | 6.87 | 6.86 | 4.83 | 5.56 | 5.28 | |
Free Cash Flow Yield | (0.001307) | 0.009264 | 0.002605 | (0.0434) | (0.0391) | (0.0411) | |
Operating Cash Flow Per Share | 0.4 | 1.77 | 0.79 | (0.49) | (0.44) | (0.46) | |
Capex To Depreciation | 3.09 | 1.7 | 3.0 | 3.28 | 2.96 | 1.55 | |
Pb Ratio | 15.93 | 21.89 | 6.55 | 6.12 | 5.51 | 4.71 | |
Ev To Sales | 11.97 | 13.84 | 3.91 | 3.04 | 3.5 | 3.33 | |
Free Cash Flow Per Share | (0.13) | 1.39 | 0.12 | (1.29) | (1.16) | (1.21) | |
Roic | (0.0119) | 0.0109 | (0.0689) | (0.3) | (0.27) | (0.29) | |
Inventory Turnover | 3.43 | 3.74 | 4.76 | 3.49 | 2.41 | 2.17 | |
Net Income Per Share | (0.56) | 0.25 | (1.47) | (3.43) | (3.09) | (3.24) | |
Days Of Inventory On Hand | 97.6 | 76.61 | 104.47 | 151.69 | 174.45 | 176.39 | |
Payables Turnover | 13.38 | 11.65 | 6.97 | 7.66 | 6.9 | 8.12 | |
Research And Ddevelopement To Revenue | 0.16 | 0.12 | 0.13 | 0.17 | 0.26 | 0.25 | |
Capex To Revenue | 0.0647 | 0.0335 | 0.0536 | 0.069 | 0.0794 | 0.0754 | |
Cash Per Share | 7.95 | 9.9 | 9.62 | 7.21 | 8.29 | 7.88 | |
Pocfratio | 236.55 | 85.15 | 57.14 | (60.35) | (54.32) | (51.6) | |
Interest Coverage | (0.65) | 2.04 | (14.33) | (23.6) | (27.14) | (28.5) | |
Capex To Operating Cash Flow | 1.31 | 0.21 | 0.85 | (1.62) | (1.46) | (1.39) | |
Pfcf Ratio | (765.31) | 107.95 | 383.83 | (23.02) | (20.71) | (21.75) | |
Days Payables Outstanding | 27.27 | 31.33 | 52.4 | 47.63 | 54.77 | 51.29 | |
Income Quality | (0.72) | 7.15 | (0.53) | 0.14 | 0.13 | 0.12 | |
Roe | (0.0939) | 0.0359 | (0.22) | (0.71) | (0.82) | (0.78) | |
Ev To Operating Cash Flow | 241.97 | 87.34 | 62.04 | (71.57) | (64.41) | (61.19) | |
Pe Ratio | (169.73) | 609.2 | (30.48) | (8.62) | (7.76) | (7.37) | |
Return On Tangible Assets | (0.0486) | 0.0173 | (0.0902) | (0.23) | (0.21) | (0.22) | |
Ev To Free Cash Flow | (782.85) | 110.72 | 416.76 | (27.29) | (24.56) | (25.79) | |
Earnings Yield | (0.007097) | (0.005892) | 0.001642 | (0.0328) | (0.12) | (0.1) | |
Intangibles To Total Assets | 0.0123 | 0.007331 | 0.004395 | 0.002914 | 0.003351 | 0.003183 | |
Net Debt To E B I T D A | (10.26) | 6.67 | (3.42) | (1.83) | (2.11) | (2.0) | |
Current Ratio | 6.14 | 6.15 | 5.14 | 3.83 | 3.45 | 3.26 | |
Tangible Book Value Per Share | 5.86 | 6.77 | 6.79 | 4.79 | 5.51 | 5.23 | |
Receivables Turnover | 6.07 | 6.35 | 6.98 | 7.08 | 6.38 | 4.69 | |
Graham Number | 8.73 | 6.18 | 15.09 | 19.31 | 22.21 | 21.1 | |
Shareholders Equity Per Share | 6.01 | 6.87 | 6.86 | 4.83 | 5.56 | 5.28 | |
Debt To Equity | 0.62 | 0.73 | 0.95 | 1.33 | 1.19 | 1.25 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.